# AdditioN of Fixed Dose Combination (FDC) Of Budesonide/Formoterol Via Elpenhaler® Device in Greek Patients With asThma accΟrding to Standard Clinical Practice.

> **NCT04835961** · — · COMPLETED · sponsor: **Elpen Pharmaceutical Co. Inc.** · enrollment: 1037 (actual)

## Conditions studied

- Asthma

## Interventions

- **OTHER:** Maintenace and As needed

## Key facts

- **NCT ID:** NCT04835961
- **Lead sponsor:** Elpen Pharmaceutical Co. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-01
- **Primary completion:** 2022-07-01
- **Final completion:** 2022-07-01
- **Target enrollment:** 1037 (ACTUAL)
- **Last updated:** 2023-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04835961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04835961, "AdditioN of Fixed Dose Combination (FDC) Of Budesonide/Formoterol Via Elpenhaler® Device in Greek Patients With asThma accΟrding to Standard Clinical Practice.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04835961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*